10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2024

10x Genomics reports 17% revenue growth, faces China headwinds

10x Genomics delivered strong revenue growth, particularly in the Americas and EMEA, while facing challenges in APAC, especially in China. The company's focus on Xenium and operational ramp reflects confidence in future growth, but challenges in China and achieving free cash flow remain. Overall, the company is well-positioned for growth but needs to navigate challenges in China and achieve free cash flow.

TXG reports 28% revenue growth, faces challenges in APAC region

TXG reported strong revenue growth but faced challenges in the APAC region, particularly in China, impacting gross margins. The company is prioritizing investments in driving Xenium adoption, impacting near-term gross margin and cash flow objectives. However, there are opportunities for growth in AMR and EMEA, as well as potential in Flex and Feature Barcode applications for clinical adoption.

10x Genomics reports 17% revenue growth, raises full-year guidance

10x Genomics reported strong revenue growth driven by the success of the Xenium platform and raised its full-year revenue guidance. The company is disciplined in spending and aims to become free cash flow positive in the near term. While facing challenges in China and with Chromium, the company sees opportunities in new product capabilities and market potential for spatial placements.

10x Genomics reports robust Q4 earnings, eyes innovation for growth

10x Genomics is poised for continued growth with a strong financial performance and a strategic focus on innovation in single-cell analysis. While facing challenges from product transitions, the company sees opportunities in expanding its product offerings and driving adoption through pricing strategies. Analyst inquiries have prompted management to reaffirm their commitment to growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024.

10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution  PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product.

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.

10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen announces the denial of 10x Genomics' petition for Inter Partes Review of the Vizgen-licensed patent asserted against 10x's Xenium Platform.

Vizgen Announces Denial of 10x Genomics' Petition for Inter Partes Review of Vizgen-Licensed Patent Currently Asserted Against 10x's Xenium Platform

Prime Medicine Inc

Recursion Pharmaceuticals

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m.

10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference

10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings

10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif. , Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024.

10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost Pre-orders now open for first two Chromium products powered by GEM-X; expected to ship in Q1 PLEASANTON, Calif. , Feb. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X, the next generation of the company's leading single cell technology.

10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology PLEASANTON, Calif. , Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the Company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit: Click Here to Join the Investigation The investigation pertains to whether executives at the company misrepresented or f.

TXG Alert: Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations

PLEASANTON, Calif. , Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024.

10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform, Xenium, which offers exceptional vision and surpasses competitors in speed, sensitivity, and specificity. 10x Genomics is poised for sustained growth with its pursuit of scientific advancements, expanding applications in various fields, and strategic partnerships.

10x Genomics: Still Waiting For Entry

PLEASANTON, Calif. , Jan. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.

10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results

PLEASANTON, Calif. , Dec. 21, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at the 42nd Annual J.P.

10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide PLEASANTON, Calif. , Dec. 20, 2023 /PRNewswire/ --  10x Genomics, Inc. , (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide.

10x Genomics Launches Xenium Catalyst Network

A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms PLEASANTON, Calif. , Dec. 19, 2023 /PRNewswire/ --  10x Genomics, Inc.  (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Nature Communications has published a 10x-conducted study using the Chromium Single Cell, Visium Spatial and Xenium In Situ platforms as part of an integrative approach to understand how tumor microenvironment differences influence invasiveness.

Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif. , Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently evaluated the technical performance of three spatial imaging platforms and found the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 formalin-fixed paraffin-embedded (FFPE) tissues compared to NanoString's CosMx and Vizgen's MERSCOPE.

High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint

PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the  NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

NanoString Technologies

Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics.

NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics

Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG).

News for 10X Genomics Stock (TXG)